| Name | Title | Contact Details |
|---|---|---|
Scott Hollander |
Assistant General Counsel - Compliance, Investigations and Litigation | Profile |
Vivek Mittal |
Global General Counsel | Profile |
Vanessa Brill |
Vice President and Regional General Counsel, the Americas | Profile |
Srinivasa Rao |
Vice President and Head of Regulatory Affairs - North America Generics | Profile |
Anjum Swaroop |
Chief IP Counsel | Profile |
Cubist Pharmaceuticals, Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, & Biotech sector.
Tioga Pharmaceuticals Inc is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Xerimis Inc is a Moorestown, NJ-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
BioVectra Inc. is a Charlottetown, PE-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Momenta is a biotechnology company with a product pipeline of both complex mixture generic and novel drugs. Our complex mixture generics and follow-on biologics effort is focused on building a thorough understanding of the structure-process-activity of complex mixture drugs to develop generic versions of marketed products. While we use a similar analytical and development approach across all of our product candidates, we tailor that approach for each specific product candidate. Our first objective is to apply our core analytical technology to thoroughly characterize the structure of the marketed product. By defining the chemical composition of multiple batches of a marketed product, we are able to develop an equivalence window which captures the inherent variability of the innovator`s manufacturing process. Using this information, we then build an extensive understanding of the structure-process relationship to design and control our manufacturing process to manufacture reproducibly an equivalent version of the marketed product. Where necessary, and as required by the U.S. Food and Drug Administration, or FDA, we will supplement an application with additional supportive structure-activity data (e.g., immunogenicity, pharmacodynamics). Our goal is to obtain FDA approval for and commercialize generic or follow-on versions of complex mixture products, thereby providing high quality, safe and affordable medicines to patients in need.